Allergan Presbyopia Treatment Hits Main Endpoint in Phase 3 Studies
October 28 2020 - 9:06AM
Dow Jones News
By Colin Kellaher
AbbVie Inc.'s Allergan unit Wednesday said a pair of phase 3
studies of its AGN-190584 ophthalmic solution met their primary
efficacy endpoint in the treatment of symptoms associated with the
progressive eye condition presbyopia.
Allergan said a statistically significant greater proportion of
participants in the studies showed improvement in near vision.
Allergan, which AbbVie acquired earlier this year in a $63
billion deal, said the studies will serve as the basis for a new
drug application with the U.S. Food and Drug Administration in the
first half of 2021.
Allergan said roughly 128 million people in the U.S. experience
presbyopia, which reduces the eye's ability to focus on near
objects and usually impacts people after age 40.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
October 28, 2020 08:51 ET (12:51 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
